EYPT vs GETY
EYPT: EyePoint Pharmaceuticals is a clinical-stage biotech developing long-acting, sustained-release ocular drug delivery technology to treat chronic retinal diseases. GETY: Getty Images is a leading digital visual content marketplace currently undergoing a strategic review of its capital structure amidst significant liquidity and litigation challenges.
Side-by-side fundamentals
| Metric | EYPT | GETY | Edge |
|---|---|---|---|
| Price as of 2026-10-22 close | $0.4281 | $0.0251 | |
| Market cap | $37M | $11M | |
| Net margin FY2025, SEC XBRL | -739.4% | -21.0% | GETY higher |
| Operating margin FY2025, SEC XBRL | -776.0% | +8.6% | GETY higher |
| ROE FY2025, SEC XBRL | -75.8% | -34.3% | GETY higher |
| ROA FY2025, SEC XBRL | -63.7% | -6.4% | GETY higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 6.07 | |
| Revenue growth (YoY) FY2025, SEC XBRL | -27.5% | +4.5% | GETY higher |
| Revenue CAGR (3y) SEC XBRL | -8.8% | +1.9% | GETY higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.31 | 1.55 | |
| 1-year return as of 2026-10-22 close | -96.3% | -98.8% | EYPT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.